These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
530 related articles for article (PubMed ID: 33347822)
41. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092 [TBL] [Abstract][Full Text] [Related]
42. The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer. Silva VS; Riechelmann RP; Mello CA; Felismino T; Taboada R Curr Cancer Drug Targets; 2022 Aug; 22(8):617-628. PubMed ID: 35209820 [TBL] [Abstract][Full Text] [Related]
44. T-cell-based immunotherapy in colorectal cancer. Feng M; Zhao Z; Yang M; Ji J; Zhu D Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958 [TBL] [Abstract][Full Text] [Related]
45. m Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498 [TBL] [Abstract][Full Text] [Related]
46. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]. Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467 [TBL] [Abstract][Full Text] [Related]
47. [Neoadjuvant immunotherapy in microsatellite stability or mismatch repair proficient colorectal cancer]. Zhang JW; Deng YH Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):193-198. PubMed ID: 35340167 [TBL] [Abstract][Full Text] [Related]
48. Advances in immunotyping of colorectal cancer. Wu Y; Zhuang J; Qu Z; Yang X; Han S Front Immunol; 2023; 14():1259461. PubMed ID: 37876934 [TBL] [Abstract][Full Text] [Related]
49. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906 [TBL] [Abstract][Full Text] [Related]
50. Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series. Zhou C; Jiang T; Xiao Y; Wang Q; Zeng Z; Cai P; Zhao Y; Zhao Z; Wu D; Lin H; Sun C; Zhang R; Xiao W; Gao Y Front Immunol; 2021; 12():784336. PubMed ID: 34975873 [TBL] [Abstract][Full Text] [Related]
51. Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? Arrichiello G; Poliero L; Borrelli C; Paragliola F; Nacca V; Napolitano S; Corte CMD; Martini G; Martinelli E Cancer Treat Res Commun; 2021; 28():100442. PubMed ID: 34391139 [TBL] [Abstract][Full Text] [Related]
52. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Mehrvarz Sarshekeh A; Overman MJ; Kopetz S Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436 [TBL] [Abstract][Full Text] [Related]
53. [Neoadjuvant immunotherapy for colorectal cancer]. Pei JP; Wu AW Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):58-67. PubMed ID: 36650001 [TBL] [Abstract][Full Text] [Related]
54. [Checkpoint inhibitors in colorectal carcinoma: are we entering a new era?]. Pox C Inn Med (Heidelb); 2023 May; 64(5):500-505. PubMed ID: 37039887 [TBL] [Abstract][Full Text] [Related]
55. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Huyghe N; Baldin P; Van den Eynde M Gastroenterol Rep (Oxf); 2020 Feb; 8(1):11-24. PubMed ID: 32104582 [TBL] [Abstract][Full Text] [Related]
56. Nivolumab for the treatment of colorectal cancer. Smith KM; Desai J Expert Rev Anticancer Ther; 2018 Jul; 18(7):611-618. PubMed ID: 29792730 [TBL] [Abstract][Full Text] [Related]
57. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges. Link JT; Overman MJ Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597 [TBL] [Abstract][Full Text] [Related]
58. [Organ preservation in locally advanced colorectal cancer with microsatellite instability-high after immunotherapy]. Hong ZG; Xiao BY; Ding PR Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):353-358. PubMed ID: 38644240 [TBL] [Abstract][Full Text] [Related]
59. Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. Picco G; Cattaneo CM; van Vliet EJ; Crisafulli G; Rospo G; Consonni S; Vieira SF; Rodríguez IS; Cancelliere C; Banerjee R; Schipper LJ; Oddo D; Dijkstra KK; Cinatl J; Michaelis M; Yang F; Di Nicolantonio F; Sartore-Bianchi A; Siena S; Arena S; Voest EE; Bardelli A; Garnett MJ; Cancer Discov; 2021 Aug; 11(8):1923-1937. PubMed ID: 33837064 [TBL] [Abstract][Full Text] [Related]
60. Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature. San-Román-Gil M; Martínez-Delfrade I; Albarrán-Fernández V; Guerrero-Serrano P; Pozas-Pérez J; Chamorro-Pérez J; Rosero-Rodríguez D; Sotoca-Rubio P; Barrill-Corpa AM; Alia-Navarro V; González-Merino C; García-de-Quevedo-Suero C; López V; Ruz-Caracuel I; Perna-Monroy C; Ferreiro-Monteagudo R Front Immunol; 2024; 15():1352262. PubMed ID: 38361927 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]